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Abstract

Introduction

Inter-a-inhibitor (Jal) is a serine protease inhibitor
present in human plasma. It has a molecular weight of
about 220 kDa which encompasses 3 chains including
two heavy chains and one light chain. The light chain,
known as bikunin, is responsible for the antitryptic activity of Jal in the inhibition of various enzymes, such
as trypsin and chymotrypsin. Under physiologic or certain pathologic circumstances, several macromolecules
related to Jal appear in plasma and urine. However, the
physiologic role of Jal remains unclear. As far as urolithiasis is concerned, two urinary macromolecules related to Jal have been isolated and shown to be potent inhibitors of calcium oxalate formation . One of these inhibitors, uronic-acid-rich protein (UAP) , has been identified and well characterized. The sequence of the first
18 amino acid residues of UAP is identical with that of
bikunin. Furthermore, the immunoreaction between
UAP and Jal antibody using immunoblot analysis was
positive. UAP isolated from the urine of stone formers
exhibited less inhibitory activity towards calcium oxalate
crystalliz.ation than that derived from the urine of healthy
subjects. This suggests a structural abnormality of the
inhibitor obtained from stone patients. The organic
matrix extracted from kidney stones contained a protein
antigenically related to Jal. We conclude that UAP is
a member of Jal family taking part in inhibiting calcium
oxalate crystalliz.ation, and modulating the formation of
stones in the urinary tract.

Mammalian blood is a rich source of proteinase inhibitors which account for about 10 % by weight of all
plasma proteins in human [46 , 69]. They constitute the
third largest group of functional proteins after albumin
and immunoglobulins. Inter-a-inhibitor (Jal) is one
among the well characterized human serine plasma proteinase inhibitors. These inhibitors seem to control diverse critical events associated with proteolysis that occur during pathologic circumstances such as cancer, fibrinolysis, and inflammation by inhibiting the action of
various enzymes including neutrophil elastase, cathepsin
G, and plasmin [20, 28 , 50] . Nevertheless, the physiological function of fol is still not well established. The
average concentration of fol in plasma of healthy human
subjects is about 450 mg/I [65]. Low amounts of other
smaller macromolecules immunologically related to Jal
are also present in plasma and urine. Their level increases in pathological conditions, suggesting that they
could be a result of an increase of Jal turnover. Many
of these macromolecules have been purified and characterized to understand the mechanism of their release and
the importance of their presence in the body fluids. A
few years ago , two macromolecules related to fol and
having the ability to inhibit calcium oxalate (CaOx) crystalliz.ation in vitro were isolated from human urine [2,
63] .
This paper is written to focus attention on the relationship between Jal and urolithiasis. We describe here
Jal and its related proteins, specifically those that may
be involved in stone formation .
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Structure of fol and its Immunologically
Related Derivatives (Figure 1)
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Jal is a glycoprotein with a molecular weight of
about 180-220 kDa. A decade ago, it was thought that
Jal contained a single polypeptide chain since it showed
a unique band on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) in the presence of
strong reducing agents [41, 51]. However, subsequent
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Figure 1. Structure oflal and its derivatives according to reference 54. Bikunin is derived from a common precursor
that codes also for al-microglobulin (al-m). It is present in a free form or complexed with one or two heavy (H)
chains constituting H2/Bikunin, inter-a-inhibitor (Ial) (Hl + H2 + bikunin), or pre-a-inhibitor (Pal) (H3 + bikunin).
A glycosaminoglycan (GAG) chain, associated with bikunin, ensures the junction between the different subunits of lal
and its related proteins.

------------------------------------------------------------------------------------------------data coming from molecular biology techniques demonstrated the presence of two or three distinct mRNAs coding for heavy (H) and light (L) chain respectively [11,
19, 25, 56, 60]. The latter is called bikunin, formerly
known as urinary trypsin inhibitor, acid-stable trypsin
inhibitor, the light chain of lal, or HI-30. Bikunin
originates from a common mRNA that also codes for another protein called al-microglobulin (al-m) [34, 37,
53, 62, 71]. As soon as they are synthesized, a cleavage occurs and both al-m and bikunin are released separately [49] . al-m has never been found associated with
Ial or its related polypeptides [56, 60]. In humans, the
scission seems to occur at the amino acid sequence ArgVal-Arg-Arg immediately preceding the bikunin subunit
of the precursor [13]. Therefore, these amino acid residues are missing in the final product. Yet, the mechanism and conditions under which the precursor is broken
away remain elusive. Now, it is recognized that Ial
comprises two heavy chains (Hl: 78 kDa and H2: 85
kDa) and bikunin (45 kDa) [10, 38, 45, 52]. The genes
of these chains are located on the chromosome 3p21.1p21. 2, 10p14-pl5, and 9q32-q34 respectively [19, 59].

Bikunin is also present in a free form in plasma and
urine [54]. Interestingly, the three chains are held together in unique complex by way of a carbohydrate
chain [32, 38]. Bikunin contains a N-linked oligosaccharide chain and an O-linked oligosaccharide chain attached to Asn45 and Ser 10 respectively [25, 29]. The
latter was further demonstrated to be a glycosaminoglycan (GAG) [17]. Several studies demonstrated that
chondroitinase and hyaluronidase can split lal into heavy
and light chains [8, 9, 61]. Recent results confirmed
that the GAG chain covalently cross-linked the subunits
oflal [40].
Another protein related to lal has also been found
and named pre-a-inhibitor (Pal) [22]. It is made of bikunin, similar to that of Ial and a heavy chain (H3: 85
kDa) coded by another mRNA different from those described earlier for Ial. This demonstrated that Pal constituted a protein distinct from Ial and not derived from
it by proteolysis [22]. A protein consisting of H2 and
bikunin is also present in the plasma [18, 21, 54]. The
nature of the cross-linking between the two polypeptide
chains of this protein appears similar to that found in
426
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Table l. Distribution of Ial and its derivatives in
normal tissues.

Pal. In all polypeptide complexes, Ial, H2/bikunin, or
Pal, bikunin seems to be responsible for their antitryptic
activity by inhibiting various enzymes, particularly trypsin and chymotrypsin [20, 28, 50) .
When Ial and bikunin are submitted to a prolonged
digestion with trypsin, they release fragments of a molecular weight of 14 and 8 kDa named HI-14 and Hl-8,
respectively [30, 72). The amino acid composition of
bikunin and Hl-14 are identical indicating that HI-14 is
the peptidic chain of bikunin and large carbohydrate
moieties should be responsible for the molecular weight
of 45 kDa of the native form of bikunin. Therefore, HI14 and HI-8 may be products of Ial or bikunin which
are fragmented during purification or in the presence of
enzymes like trypsin.

Type of
tissue

Biosynthesis and Localization of fol
and its Derivatives (Table 1)

Method

References

Liver

Immunohistology
mRNA analysis

[15)
[37·, 55, 56, 67.)

Lung

Elisa
Immunohistology

[15)
[73)

Kidney

Immunohistology

[15, 44, 73, 74]

Brain

Immunohistology

[15, 73, 74]

Stomach

lmmunohistology
mRNA analysis

[73, 74]
[67.]

Testis

lmmunohistology

[15]

•Distribution of a 1-microglobulin/Bikunin mRNA

---------------------------------

Ial is synthesized mainly in the liver and excreted
in plasma [10, 62). This finding was confirmed at the
molecular level. Indeed, the mRNA encoding for the
Ial subunits was found expressed only in the liver [56).
Nevertheless, the expression of the gene encoding for
the heavy chain H3 has also been observed in the brain
[55]. By using dot blot analysis, the mRNA encoding
for the precursor a 1-microglobulin/bikunin was found in
rat at high level in the liver and kidney, low in the brain
and testis [33). Further studies by the same authors
however, confirmed its synthesis in the liver only [37).
In pig, the expression of mRNA of this precursor was
observed at high level in the liver and, at a low level, in
the stomach [67).
The immunochemical distribution of Ial and its derivative fragments in different organs has been investigated (Table 1). Under normal conditions, Ial immunoreactivity was found in the liver, kidney, testis, gross
intestine, cutis and brain [15, 73, 74). Surprisingly, the
immunoreaction was also detected in cultured fibroblasts
[14) and human mast cells [44). Also using al-microglobulin antibody, a positive immunoreaction was observed in human lymphocytes and macrophages [33) .
The presence of Ial related proteins in the urinary tract
has been specially investigated [44) . Ial immunoreactivity was found to be exclusively present in renal proximal tubules due to the reabsorption of bikunin by this
segment of nephron. Ial immunoreactivity was also detected in human mast cells in the connective tissue of a
bladder papilloma and in the rat bladder epithelium [44).

however, these roles have not been resolved. IaI is especially sensitive to some enzymes such as elastase and
cathepsin G which are activated during several diseases
including cancer, inflammation, and renal failure . Due
to their smaller size, proteins obtained from Ial turnover
may be able to diffuse throughout the affected tissues
and may contribute to the cells' protection against proteolysis. Nevertheless, Ial accounts for less than 5% of
the total trypsin inhibitory activity [6, 57] which does
not favor such a protective role. Moreover, the results
showed no significant consumption of Ial during the inflammation process, although proteins related to IaI
were present [58]. However, these results were contested in other studies [26, 45].
McKeehan et al. [39] isolated from human hepatoma cells two endothelial cell growth factors structurally
similar to pancreatic secretory trypsin inhibitor and
bikunin. Both proteins are absent or present in low
amounts in normal plasma and urine. They stimulate
endothelial cell growth and their concentrations were
increased during inflammation and cancer. These findings suggest that Ial and their related proteins may be
involved in neovascularii.ation and desmoplasia, associated with tumor and tissue damage process.
Lastly, S0rensens work [63] and particularly our
studies [2] demonstrated that a glycoprotein related to
Ial, most probably a urinary bikunin, is a potent inhibitor of CaOx crystal growth in vitro and may inhibit and
reduce the formation of CaOx crystals in urinary tract.

Physiological Role of fol and its Related Proteins

Relationship of fol and its Derivatives to Urolithiasis

The presence of Ial in various tissues suggests that
it may fulfill different physiological functions. So far,

S0rensen et al. [63] isolated a protein from normal
human urine using two anion exchange chromatography
427
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Table 2. Comparison of physico-chemical properties of S0rensens protein, uronic-acid-rich protein (UAP), and urinary
bikunin.
Proteins

Molecular
weight (kDa)

CaOx growth
inhibitory activity

Effect of pronase on
CaOx inhibition

Effect of chondroitinase

Sorensen's protein

40

+++

No effect

U ronic acid removed

UAP

35

+++

Activity destroyed

Produces a protein of 20 kDa

Urinary bikunin

45

+

Activity destroyed

Produces a protein of 20 kDa

steps (on DEAE-Sephacel and Mono Q column) and one
affinity chromatography (vinylsulfone agarose). The
protein exhibited quite the same characteristics as urinary bikunin: molecular weight in SDS-PAGE: 40 kDa,
in gel filtration: 67 kDa, identical N-terminal sequence,
and presence of uronic-acids. The authors found that
this Icd fragment was a potent inhibitor of CaOx crystai
growth and stated that it is the only protein which might
have an inhibitory activity in the urine. By chondroitinase digestion, the uronic acids were removed but the
inhibitory capacity of the protein remained. Moreover,
pronase digestion had no effect upon its inhibitory capacity and the authors considered that this data might be explained by the antiprotease activity of the inhibitor [63].
Unfortunately, further characterization of this inhibitor
has so far not been reported.
In an attempt to find another CaOx inhibitor, we
fractionated human urinary macromolecules using three
chromatographic procedures including DEAE-Sephacel
gel followed by Sephacryl S-300 chromatography, and
finally Mono Q column using an FPLC system. We
were able to isolate and purify a macromolecule with a
molecular weight of 35 kDa as estimated by SDS-P AGE
[2]. The protein showed a potential activity to slow the
rate of CaOx crystal growth efficiently. Moreover, as
described in detail in reference [2], its crystallization
inhibitory activity was greater than that of nephrocalcin
or nephrocalcin-like macromolecule considered, at the
time, the principal urinary inhibitor of CaOx crystallization [42]. The inhibitor was named uronic-acid-rich protein (UAP) due to its uronic acid contents. The molecular characteristics of UAP indicated structural similarities with bikunin. The sequence of the first 18 amino
acid residues of the protein was identical with that of
bikunin [l, 4]. Moreover, by using a polyclonal fol antibody by immunoblotting analysis, a positive immunoreaction was observed confirming the close relationship
between UAP and fol [l].
UAP was also isolated from rat urine and compared
to that isolated from human urine [l] . Both showed
identical amino acid composition, similar amino acid sequence, and similar crystallization inhibitory activity.
UAP was assayed on CaOx crystal growth model before

and after treatment with pronase, chondroitinase AC,
and hyaluronidase as described by S0rensen et al. [63].
Our data demonstrated that chondroitinase and hyaluronidase had no effect on CaOx growth inhibitory activity of UAP, but yielded a protein with a molecular
weight of 20 kDa [4]. This finding suggests that UAP
comprises a large giycosaminoglycan chain responsible
for its molecular weight at 35 kDa. In contrast to
S0rensens study, pronase treatment degraded the total
inhibitory activity of UAP suggesting that the inhibitor
isolated by us is different from the one purified by
S0rensen et al. [63]. A comparison of physico-chemical
proprieties of these proteins is shown in Table 2. We
hypothesize that both UAP and S0rensens protein may
exist in urine as separate entities or they may be the
same protein purified by slightly different methods.

Is UAP Bikunin?
The results of amino acid sequence and immunoblotting analysis suggest that UAP is a protein related to fol
family and could be bikunin. To clarify this relationship, in our recent study (Atmani et al., Eur. J. Biochem., in press), both UAP and urinary bikunin were
isolated and purified from human urine. Their CaOx
growth inhibitory activity was assayed before and after
pronase treatment. The inhibition assay consists in using
a mixture of 1 ml supersaturated solution of CaCl2 (2
mmol/1 in Tris 0.05 mol/l, NaCl 0.15 mol/1, pH 7 .3) in
the presence of [45 Ca]CaC1 2 and 1 ml ammonium oxalate (2 mmol/l in Tris 0.05 mol/1, NaCl 0.15 mol/l, pH
7. 3). The tubes containing proteins were compared with
those without added proteins. At the end of the assay,
tubes were centrifuged at 2000 g for 5 minutes and 0.5
ml of supernatant was withdrawn for radioactivity determination in a liquid scinti llation counter. The inhibitory
activity was determined before and after enzymatic digestion. The results shown in Figure 2 demonstrate that
UAP exhibited a strong CaOx growth inhibitory activity
while urinary bikunin was less inhibitory. The CaOx
inhibitory activity of both proteins disappeared after
pronase digestion. Structurally, UAP and urinary bikunin have many similarities. Their molecular weight
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a human urinary protein which we named nephrocalcinlike [2] due to its biochemical similarities with nephrocalcin described by Nakagawa et al. [42]. The molecular weight of the protein was about 16 kDa, it was able
to bind to Tamm-Horsfall protein, and it showed an important inhibitory activity toward CaOx crystallization.
However, this inhibitory activity was lower than that of
UAP. Unfortunately, at that time, we did not determine
its amino acid sequence. In a recent study, Ryalls
group [66] reported the partial amino acid sequence of
a protein claimed to be nephrocalcin. It showed an
identity with HI-14, a fragment ofbikunin. As we mentioned earlier, prolonged digestion of fol or bikunin with
trypsin, results in the production of two peptides, Hl-14
and HI-8 . Consequently, HI-14 is not a physiological
product. Moreover, many features of nephrocalcin do
not match with Hl-14 fragment. For instance, nephrocalcin has 2-3 ')'-carboxyglutamic acid (Gla) residues and
is synthesized in kidney, but Hl-14 does not contain Gla
and is not produced in kidney . Therefore, the results
obtained by Ryalls group remain speculative.

80
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60
,:::

._g

-~
,g
:.a
40
......
~

b

20
C

d
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Figure 2. Calcium oxalate growth inhibitory activity of
UAP and urinary bilcunin before (a, c) and after treatment (b, d) with pronase respectively.

fol and its Related Proteins in Lithiasis Disease
Many reports indicate that urine of stone formers
contains macromolecules that inhibit CaOx crystal formation, but not efficiently as the same inhibitors found
in the urine of normals [3 , 27 , 43]. With regards to
fol, its plasma concentration was reduced during various
pathologic conditions including renal failure [24, 45 , 46,
68] . Simultaneously, urinary bilcunin concentration was
increased suggesting an enhancement of fol turnover.
Although, these findings were not confirmed in other
studies suggesting that fol and its related proteins could
be synthesized in separate pathways [13, 47, 58]. Accordingly, since UAP is related to fol, may be its excretion is increased in the urine of patients with renal disease. Thereby, an increase in CaOx growth inhibitory
activity is anticipated. Unfortunately, this was not the
case, suggesting that UAP obtained from stone formers
may be structurally abnormal and does not inhibit crystal
precipitation efficiently. Accordingly, we have isolated
UAP from the urine of stone formers and its inhibitory
activity was compared to that purified from the urine of
healthy subjects [3]. The results demonstrated that UAP
obtained from stone patients exhibited less inhibitory activity. Partial structure of this glycoprotein showed that
it contained less sialic acid than that of normals [3].

is 35 and 45 kDa respectively. They have similar amino
acid composition and similar amino acid sequence of
first 18 residues. Furthermore, they are immunologically related to fol. However, functionally they appear
different. A comparison of physico-chemical proprieties
of UAP and urinary bilcunin is reported in Table 2.
As we have reported above, bikunin is present in
free form or attached to different complexes related to
fol. The free form can easily pass into urine through
glomeruli due to its low molecular weight. Metabolism
oflal or its related proteins (enzymatically for instance)
may yield another form of bikunin. The latter may be
modified during this process and present some differences compared to the preexisting free form of bikunin.
Furthermore, the isolation of bikunin with different molecular weights, has been reported by several investigators [7, 9, 16, 23, 61]. These discrepancies may be due
to differences in various technical procedures used in the
isolation and purification of proteins. The carbohydrate
content of the protein and the presence of a GAG chain
that can modify its electrophoretic mobility should be
taken into consideration since many results are still in
disagreement. However, it has been reported that the
carbohydrate chain does not contribute to CaOx inhibitory activity of proteins related to fol [2, 63]. Experiments are in progress to clarify this matter.
Nephrocalcin with a molecular weight of about 14
kDa, is one of the well-known urinary inhibitors of
CaOx crystallization [42]. So far, the amino acid sequence of this inhibitor remains unknown. We isolated

fol Related Proteins in Stones
Regardless of mineral composition, all urinary
stones contain an organic material refereed to as matrix
protein [35, 36]. The latter represents about 2-5 % by
429
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[7] Balduyck M, Hayem A, Kerckaert JP, Miron C,
Miron J (1982) Isolation of human urinary trypsin inhibitor. Biochem Biophys Res Comm 109: 1247-1255.
[8] Balduyck M, Laroui S, Miron C, Miron J
(1989) A proteoglycan related to the urinary trypsin inhibitor (UTI) links the two heavy chains of inter-a-trypsin inhibitor. Biol Chem Hoppe-Seyler 370: 331-336.
[9] Balduyck M, Miron C, Loutfi H, Richet C,
Roussel P, Miron J (1986) The major human urinary
trypsin inhibitor is a proteoglycan. Eur J Biochem 158:
417-422.
[10] Bourguignon J, Sesboiie R, Diarra-Mehrpour
M, Daveau M , Martin JP (1989) Human inter-a-trypsin
inhibitor. Synthesis and maturation in hepatoma HepG2
cells. Biochem J 261: 305-308.
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Martin JP, Salier JP (1983) Inter-alpha-trypsin inhibitor
(ITI): Two mRNAs in baboon liver argue for a discrete
synthesis of ITI and ITI derivatives. FEBS Letters 162:
379-383.
[12] Boyce WH (1968) Organic matrix of human
urinary concretions. Am J Med 45: 673-683.
[13] Bratt T , Olsson H, Sjoberg EM , Jergil B,
Akerstrom B (1993) Cleavage of a 1-microglobulin-bikunin precursor is localized to the Golgi apparatus of rat
liver cells. Biochim Biophys Acta 1157: 147-154.
[14] Brissenden JE, Cox DW (1982) az-macroglobulin production by cultured human fibroblasts. Som Cell
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tissues and body fluids . Cell Mol Biol 38: 436-471.
[16] Chawla RK, Lawson DH, Ahmad M, Travis J
(1992) Cancer-related urinary proteinase inhibitor,
EDCl: A new method for its isolation and evidence for
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is located on serine-10 of the urinary trypsin inhibitor.
Int J Biochem 23: 1201-1203.
[18] Daveau M, Rouet P, Scotte M, Hiron M ,
Lebreton JP, Sallier JP (1993) Human inter-a-trypsin
inhibitor family in inflammation: Simultaneous synthesis
of positive and negative acute-phase proteins. Biochem
J 292: 485-492.

weight and consists predominantly of proteins [12]. Its
role in the formation of urinary stones remains a subject
of research. To better understand this role, many investigators attempted to analyze proteins extracted from urinary stones. Unfortunately, few works were devoted to
a search for fol and its related peptides and to quantify
them. Petersen et al. [48] have found hemoglobin and
two serine proteases in the extract of CaOx kidney
stone. A protease inhibitor, al-antitrypsin, has been
extracted and quantified suggesting that some stones are
in contact with blood during their development [70].
Hoyer [31] has extracted several proteins from CaOx
monohydrate stones and quantified them. His results
showed that uropontin, or osteopontin, constituted the
major protein in the extract (90 µg/100 mg). TammHorsfall protein, albumin, and fol fragment represent
less than 10 µg/100 mg of stones. Recently, in our laboratory we identified proteins extracted from CaOx crystals produced in vitro in human urine by adding sodium
oxalate [5]. Among the proteins, we detected a fragment of fol, which could be bikunin, but in lesser
amounts compared to prothrombin Fl and osteopontin.
More experiments are in progress.
Concluding Remarks

It seems that UAP is biochemically similar to bikunin, the light chain of fol. But functionally these two
proteins appear different. fol becomes a family of proteins involved in modulating calcium oxalate crystallization and stone formation . Another plasma protein, the
F 1 fragment of prothrombin has also been implicated in
calcium oxalate stone formation [64]. Apparently, the
crystallization of calcium oxalate is modulated by a variety of macromolecules including many plasma proteins.
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dues. However, Hl-14 or any protein related to fol
does not have any Gia residue. Interestingly, in a recent
work, Tang et al. [66) reported that NC is Hl-14 by using similar techniques described by Nakagawa to isolate
NC. The authors suggested that NC was contaminated
by other proteins containing Gia, like prothrombin Fl,
to explain the presence of these residues in the preparation of NC. Nonetheless, another feature of NC is it is
synthesized in kidney, but Hl-14 is not. Therefore, similarity or identity of NC to Hl-14 remains speculative
and needs confirmation by, e.g., using NC antibody.

B. Hess: It should be acknowledged that there are certain requirements for an inhibitor/modifier to be of clinical significance for calcium stone formation, such as: (1)
abundance in urine, (2) occurrence of calcium binding
sites in the molecule, (3) structural and functional abnormalities or significantly reduced excretion in active stone
formers versus healthy people, and (4) possibly some
therapeutic implications, i.e., altering physico-chemical
conditions of urines, modifying the diet or prescribing
certain drugs should improve the functional status of a
given macromolecule towards more inhibition of crystallization, mainly crystal aggregation.
Authors: In this paper, we do not attempt to describe
UAP as a superinhibitor to be considered and the others
to be discarded. In the paper where UAP was described
for the first time [2], we pointed out that one inhibitor
alone cannot be responsible for the total urinary inhibitory activity. Moreover, in a second paper [3], we reported that UAP extracted from the urine of stone forming subjects was less inhibitory compared to that isolated
from the urine of healthy persons. We suggested that
this diminution does not account for the total urinary
inhibitory activity, but that other protein inhibitors also
may be defective.

Discussion with Reviewers
B. Hess: How do the authors explain the suggested reabsorption of fol in the proximal tubule, i.e., how does
a protein with a molecular weight of 180-220 kDa get
across the tubular membrane into the tubular fluid?
Reviewer VII: The question of whether bikunin/UAP
(or fol) is synthesized in the kidney, or is merely filtered at the glomerulus is not directly addressed. Do the
authors have any data to define more precisely the
nature of the fol reactivity?
Authors: fol is mainly synthesized in the liver and secreted in plasma. Recent work studying the expression
of mRNA coding for fol confirmed its exclusive synthesis in the liver [55]. The presence of a positive fol
immunoreactivity in kidney is due to the presence of bikunin which has a molecular weight in a range of 35-45
kDa, and can easily pass through the glomerular filters,
thus, it can be recognized by fol polyclonal antibody.

M. Daudon: The authors suggest that variation in urinary excretion of fol related proteins may occur in various pathological conditions responsible for an increased
excretion of bikunin. Do the authors have some information about the normal range of UAP and bikunin excretion in human urine?
Authors: The normal range of urinary excretion of fol
related proteins is about 2 to 10 mg/day according to the
method used [77, 78). This excretion can be enhanced
to 50-100 fold or even more in certain pathological
conditions such as cancer [75, 76).
M. Daudon: How can the authors explain the weaker
inhibitory activity of UAP reported in this paper as
compared to that reported in a previous paper [4]?
Authors: The weaker inhibitory activity of UAP in this
study is not significant compared to that reported in the

B. Hess: Similarity of nephrocalcin (NC) and Hl-14 of
fol/bikunin: nephrocalcin contains Gia; what is the Giacontent of Hl-14 of fol/bikunin?
Authors: Nephrocalcin is known to have 2-3 Gia resi433

